News

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed 3 late breaking abstracts in the hepatocellular carcinoma space currently influencing the field.

Exelixis, Inc has expanded their clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the novel triplet of nivolumab, relatlimab, and XL092 in the phase 1b STELLAR-002 trial.

Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.

Early results from the phase 2a MYLOX-1 study show a reduction of collagen fibrosis of the bone marrow in patients with myelofibrosis on the LOXL2 inhibitor GB2064.

Analysis from the phase 3 CALGB/SWOG-80405 trial reveals that acquired genomic alterations in patients treated with cetuximab in combination with chemotherapy in the first-line were not common.

Findings from the PERLA trial examining the combination of dostarlimab with pemetrexed followed by cisplatin or carboplatin will be presented at an upcoming medical conference. GSK hints that the combination improves objective response compared with pembrolizumab and chemotherapy.

The first trial investigating a chimeric antigen receptor therapy to target GPRC5D in patients with resistant multiple myeloma reveals remissions in 70.6% of the enrolled patients.

Cary Gross, MD, discusses the background of his research on patients with lung cancer and Medicaid.

In an interview with Targeted Oncology, Naval G. Daver, MD, discussed the approved and investigational CD47 monoclonal antibodies for patients with acute myeloid leukemia and myelodysplastic syndrome and where research is taking this space.

Updated results from the L-MIND trial show continued efficacy and safety data for the combination of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and myelodysplastic syndrome.

Results from the phase 3 TRITON3 study show that rucaparib improves survival in multiple metastatic castration-resistant prostate cancer populations.

Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.

After results from a phase 2 trial demonstrated durability with sapanisertib, the FDA granted fast track designation to the agent for patients with unresectable or metastatic squamous non–small cell lung cancer.

Building on data showing its preclinical anti-tumor activity, CUE-101 will be examined in a phase 1b study and has been granted FDA fast track designation.

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.

In an interview with Targeted Oncology, Peter A. McSweeney discussed the ways in which community oncology centers are implementing chimeric antigen receptor T-cell therapy into their practice and the challenges that come with it.

Results from the phase 3 Study 302 of denileukin diftitoc in patients with persistent of recurrent cutaneous T-cell lymphoma led to the submission of a biologics license application for the drug.

Here is a look back at the FDA happenings from the month of September 2022

To determine the effectiveness of nirogacestat at 150mg twice a day in patients with ovarian granulosa cell tumors, the agent has been administered to the first patient in a phase 2 trial.

Traditionally, MCL was dichotomized based on the age of the patient and their ability to tolerate intensive therapy, [but] now we have to take into consideration biological differences across patients that go well beyond age, says Andre H. Goy, MD.

Results from the POLARIX clinical trial support the use of polatuzumab vedotin plus rituximab as frontline treatment for diffuse large B-cell lymphoma.

Findings from the TAS-120-101 study have led the FDA to approve futibatinib for the treatment of patients with FGFR2-positive advanced cholangiocarcinoma.

The FDA has approved bevacizumab-abcd for use in nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic colorectal cancer, persistent, recurrent, or metastatic cervical cancer, metastatic renal cell carcinoma, and epithelial ovarian, fallopian tube, and primary peritoneal cancer.

The humanized monoclonal antibody JSP191 showed an 100% complete donor chimerism and resulted in no treatment-related adverse events when administered to patients with Fanconi anemia.

Melhem Solh, MD, discusses his research on post-transplant outcomes of patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.

In an interview with Targeted Oncology following the tweet chat, Cyrus M. Khan, MD, discussed the emerging and recent data he thinks could influence the case we discussed.

Based on preclinical studies which have shown the clinical benefit of Olvi-Vec, a phase 3 trial evaluating the agent in combination with platinum-doublet chemotherapy and bevacizumab has commenced in patients with platinum-resistant/refractory ovarian cancer.

Pain is a clinical challenge for many oncology patients and clinicians, and there's a growing body of evidence showing that integrative therapies can be useful in pain management, according to Heather Greenlee, ND, PhD.

Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.